Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II trial of umbilical cord mesenchymal stem cells for pediatric refractory acute graft-versus-host disease
CTR20262408Phase 2Active
- Sponsor
- Tianjin Angsai Cell Gene Engineering Co., Ltd.
- Start
- Jun 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering) in Acute Graft-Versus-Host Disease (aGvHD) (5 arms), sponsored by Tianjin Angsai Cell Gene Engineering Co., Ltd. Primary endpoints: Drug-related adverse events during the clinical study period and Overall response rate of acute graft-versus-host disease. Started Jun 2026; status: active.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering)
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20262408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262408.